Research analysts covering Genenta Science S.p.A..
Recent press releases and 8-K filings for GNTA.
Genenta Science S.p.A. Announces Proposed Name Change and Strategic Acquisition
GNTA
M&A
New Projects/Investments
- Genenta Science S.p.A. intends to change its corporate name to Saentra Forge S.p.A. and its Nasdaq ticker symbol to SAEN, pending shareholder approval at an Extraordinary Shareholders’ Meeting on March 25 or 26, 2026. This change is linked to a strategic expansion to become an industrial consolidator in biotech, defense, aerospace, and national security sectors.
- On January 24, 2026, the company entered into an Investment Agreement to acquire an initial 19.5% equity ownership in A.T.C. S.r.l., a private Italian manufacturer of high-precision tactical rifles and weapon systems, for €1.275 million.
- The agreement provides an opportunity to acquire up to 51% equity ownership in A.T.C. S.r.l. for a total of €5.1 million, contingent on A.T.C. meeting specific turnover and EBITDA performance milestones and maintaining necessary licenses.
Jan 27, 2026, 11:05 AM
Genenta Science S.p.A. Announces Strategic Transformation and Name Change
GNTA
M&A
New Projects/Investments
- Genenta Science S.p.A. is undergoing a strategic transformation to become a next-generation strategic industrial consolidator focused on acquiring privately held businesses in national-security regulated sectors, including defense, aerospace, and biotechnology/biosecurity.
- The company plans to change its corporate name to Saentra Forge S.p.A. and its Nasdaq ticker symbol to SAEN, pending shareholder approval at a meeting scheduled for March 25-26, 2026.
- The first industrial integration is with ATC, a defense-sector company, for which Genenta expects to fund a total of EUR 5.1 million through a performance-based and staged acquisition.
- The Praexidia Foundation has joined as a long-term strategic shareholder, and Genenta expects its cash, cash equivalents, and marketable securities to be approximately $33 million at December 31, 2025.
Jan 27, 2026, 11:03 AM
Genenta Science S.p.A. Expands Board, Adjusts Compensation, and Authorizes Capital Increases
GNTA
Board Change
Executive Compensation
Debt Issuance
- On October 29, 2025, Genenta Science S.p.A. shareholders approved an increase in the Board of Directors from three to five members and appointed Miguel Maria Mutti and Giacomoantonio Paracchi as new directors.
- The overall annual remuneration for the entire Board of Directors has been redetermined to €165,000, with the newly appointed directors granted an aggregate annual gross compensation of €60,000.
- The Board of Directors resolved on October 26, 2025, to increase the share capital for one or more Shelf Offerings up to the euro equivalent of $100,000,000, with an exclusion of pre-emptive rights, by May 31, 2026.
- Additionally, on February 26, 2025, the Board approved the issuance of mandatory convertible bonds for a total of €20,000,000 by June 30, 2025, to be offered to the Enea Foundation, with a subsequent capital increase to service the conversion.
Nov 3, 2025, 11:24 PM
Genenta Science Announces Pricing of Registered Direct Offering
GNTA
New Projects/Investments
- Genenta Science (GNTA) has entered into an agreement for a Registered Direct Offering to sell 4,285,715 American Depositary Shares (ADSs) at an offering price of $3.50 per ADS.
- This offering is expected to generate gross proceeds of approximately $15.0 million and is anticipated to close on or about October 28, 2025.
- The company intends to use the net proceeds from the offering for working capital and general corporate purposes.
- Maxim Group LLC and Rodman & Renshaw LLC are acting as placement agents, and Genenta has agreed to pay them a cash fee equal to 6.0% of the aggregate gross proceeds, plus an expense allowance of up to $75,000.
Oct 28, 2025, 10:17 AM
Genenta Science S.p.A. Reports Financial Results for Six Months Ended June 30, 2025
GNTA
Earnings
Debt Issuance
New Projects/Investments
- Genenta Science S.p.A. reported a net loss of €3,826,585 for the six months ended June 30, 2025, an improvement from a net loss of €4,038,506 for the same period in 2024.
- The company's total operating expenses decreased to €3,383,093 for the six months ended June 30, 2025, from €4,518,368 in the prior year period, primarily due to lower research and development and general and administrative expenses.
- As of June 30, 2025, Genenta had €17.7 million in cash, cash equivalents, and marketable securities, which is estimated to fund operations for at least the next twelve months.
- Financing activities provided €10.5 million for the six months ended June 30, 2025, significantly up from €0.3 million in the prior year, driven by a €7.5 million mandatory convertible bond issuance and €3.0 million from its At-the-Market (ATM) program.
- The company is a clinical-stage biotechnology company with no product revenue, an accumulated deficit of €59.9 million as of June 30, 2025, and expects to require additional funding to support its long-term strategy.
Oct 10, 2025, 8:06 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more